Hologic (NASDAQ:HOLX) Coverage Initiated at Redburn Partners

Investment analysts at Redburn Partners began coverage on shares of Hologic (NASDAQ:HOLX) in a report issued on Thursday, Briefing.com reports. The brokerage set a “neutral” rating on the medical equipment provider’s stock.

A number of other analysts have also recently commented on the stock. Evercore ISI upgraded shares of Hologic from an “in-line” rating to an “outperform” rating and set a $78.00 target price for the company in a research note on Tuesday, July 6th. Zacks Investment Research upgraded shares of Hologic from a “strong sell” rating to a “hold” rating and set a $71.00 target price for the company in a research note on Tuesday, June 29th. Raymond James lifted their target price on shares of Hologic from $78.00 to $88.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 3rd. William Blair restated an “outperform” rating on shares of Hologic in a research note on Friday, July 30th. Finally, Jefferies Financial Group assumed coverage on shares of Hologic in a research note on Thursday, July 29th. They set a “buy” rating and a $95.00 price objective for the company. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Hologic presently has a consensus rating of “Buy” and an average price target of $85.50.

Shares of Hologic stock opened at $70.16 on Thursday. The firm’s 50 day moving average price is $76.26 and its 200-day moving average price is $71.04. The company has a quick ratio of 1.31, a current ratio of 1.65 and a debt-to-equity ratio of 0.69. Hologic has a 52-week low of $60.10 and a 52-week high of $85.00. The company has a market cap of $17.78 billion, a P/E ratio of 8.99, a PEG ratio of 0.69 and a beta of 1.17.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, July 28th. The medical equipment provider reported $1.33 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.21. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a net margin of 35.98% and a return on equity of 67.74%. During the same period last year, the business earned $0.75 EPS. As a group, equities research analysts forecast that Hologic will post 7.76 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of HOLX. E Fund Management Co. Ltd. acquired a new position in shares of Hologic in the 1st quarter valued at $136,000. JPMorgan Chase & Co. increased its holdings in Hologic by 62.7% in the 1st quarter. JPMorgan Chase & Co. now owns 794,195 shares of the medical equipment provider’s stock worth $59,072,000 after acquiring an additional 305,984 shares in the last quarter. Ensign Peak Advisors Inc increased its holdings in Hologic by 18.4% in the 1st quarter. Ensign Peak Advisors Inc now owns 36,227 shares of the medical equipment provider’s stock worth $2,694,000 after acquiring an additional 5,640 shares in the last quarter. Geode Capital Management LLC increased its holdings in Hologic by 8.8% in the 1st quarter. Geode Capital Management LLC now owns 5,468,005 shares of the medical equipment provider’s stock worth $405,955,000 after acquiring an additional 442,441 shares in the last quarter. Finally, Allianz Asset Management GmbH increased its holdings in Hologic by 67.8% in the 1st quarter. Allianz Asset Management GmbH now owns 738,419 shares of the medical equipment provider’s stock worth $54,923,000 after acquiring an additional 298,302 shares in the last quarter. Hedge funds and other institutional investors own 91.84% of the company’s stock.

About Hologic

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

See Also: What are popular green investing opportunities?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.